Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10412377 | 0.87 | TRPV1 (0.78) | TRPV1HPGDEPHX2ALDH1A1CYP1A2 | |
| SCHEMBL17335585 | 0.85 | EPHX2 (0.77) | TRPV1HPGDEPHX2ALDH1A1CYP1A2 | |
| SCHEMBL8269774 | 0.85 | TRPV1 (0.59) | TRPV1HPGDEPHX2ALDH1A1CYP1A2 | |
| SCHEMBL17335563 | 0.85 | EPHX2 (0.77) | TRPV1HPGDEPHX2ALDH1A1CYP1A2 | |
| SCHEMBL17335642 | 0.84 | EPHX2 (0.79) | TRPV1HPGDEPHX2ALDH1A1CYP1A2 | |
| SCHEMBL17335724 | 0.83 | HPGD (0.91) | TRPV1HPGDEPHX2ALDH1A1 | |
| SCHEMBL1456919 | 0.83 | P2RX7 (0.49) | HPGD | |
| SCHEMBL31036978 | 0.83 | P2RX7 (0.49) | HPGD | |
| SCHEMBL1456923 | 0.83 | P2RX7 (0.49) | HPGD | |
| SCHEMBL3809498 | 0.82 | EPHX2 (0.84) | TRPV1HPGDEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | MYRIAD PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014763-A1 | beta-sheet mimetics and composition and methods relating thereto | TPSAB1, TPSB2, TPSD1 | TRPV1 1754/4885HPGD 2936/4885EPHX2 1160/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | TRPV1 111/4885HPGD 137/4885EPHX2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.